BR112014000087A2 - derivados de amina cíclica como antagonistas do receptor ep4 - Google Patents
derivados de amina cíclica como antagonistas do receptor ep4Info
- Publication number
- BR112014000087A2 BR112014000087A2 BR112014000087A BR112014000087A BR112014000087A2 BR 112014000087 A2 BR112014000087 A2 BR 112014000087A2 BR 112014000087 A BR112014000087 A BR 112014000087A BR 112014000087 A BR112014000087 A BR 112014000087A BR 112014000087 A2 BR112014000087 A2 BR 112014000087A2
- Authority
- BR
- Brazil
- Prior art keywords
- receptor antagonists
- cyclic amine
- amine derivatives
- derivatives
- cyclic
- Prior art date
Links
- 101150109738 Ptger4 gene Proteins 0.000 title 1
- -1 cyclic amine Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/02—Lithium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2011/061226 WO2013004290A1 (en) | 2011-07-04 | 2011-07-04 | Cyclic amine derivatives as ep4 receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014000087A2 true BR112014000087A2 (pt) | 2017-02-14 |
| BR112014000087B1 BR112014000087B1 (pt) | 2021-08-17 |
Family
ID=44509230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014000087-5A BR112014000087B1 (pt) | 2011-07-04 | 2011-07-04 | Derivados de amina cíclica como antagonistas do receptor ep4 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9181279B2 (pt) |
| EP (1) | EP2729445B1 (pt) |
| JP (1) | JP5813223B2 (pt) |
| KR (1) | KR101760164B1 (pt) |
| CN (1) | CN103702980B (pt) |
| AR (1) | AR087052A1 (pt) |
| AU (1) | AU2011372747B2 (pt) |
| BR (1) | BR112014000087B1 (pt) |
| CA (1) | CA2839116C (pt) |
| DK (1) | DK2729445T3 (pt) |
| ES (1) | ES2559513T3 (pt) |
| HK (1) | HK1195901A1 (pt) |
| HU (1) | HUE028439T2 (pt) |
| IN (1) | IN2014CN00719A (pt) |
| PL (1) | PL2729445T3 (pt) |
| RU (1) | RU2565596C2 (pt) |
| TW (1) | TWI546285B (pt) |
| WO (1) | WO2013004290A1 (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091429A1 (es) | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| AU2014229065B2 (en) * | 2013-03-15 | 2017-03-09 | Cayman Chemical Company, Inc. | Methods of synthesizing a difluorolactam analog |
| TWI636046B (zh) * | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| NO3009426T3 (pt) | 2013-06-12 | 2018-09-29 | ||
| CA2928593A1 (en) * | 2013-12-17 | 2015-06-25 | Eli Lilly And Company | Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators |
| TWI659019B (zh) | 2014-02-28 | 2019-05-11 | 日商帝人製藥股份有限公司 | 吡唑醯胺衍生物 |
| MX2017009037A (es) * | 2015-01-09 | 2017-10-04 | Ono Pharmaceutical Co | Compuestos espiro triciclicos. |
| BR112018007664B1 (pt) | 2015-10-16 | 2023-12-19 | Eisai R&D Management Co., Ltd | Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| EP3625224B1 (en) | 2017-05-18 | 2021-08-04 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| US11446298B2 (en) | 2017-05-18 | 2022-09-20 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| WO2018210987A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| CA3060394A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as pge2 receptor modulators |
| HUE056080T2 (hu) | 2017-05-18 | 2022-01-28 | Idorsia Pharmaceuticals Ltd | Fenilszármazékok mint PGE2 receptor modulátorok |
| CA3105786A1 (en) * | 2018-07-12 | 2020-01-16 | Rottapharm Biotech S.R.L. | (r)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as ep4 receptor antagonist |
| EP3722319A1 (en) | 2019-04-09 | 2020-10-14 | Rottapharm Biotech S.r.l. | Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours |
| GB201914585D0 (en) | 2019-10-09 | 2019-11-20 | Heptares Therapeutics Ltd | Prostaglandin ep4 receptor antagonist compounds |
| EP3827828A1 (en) | 2019-11-29 | 2021-06-02 | Rottapharm Biotech S.r.l. | (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or its salt also in polymorphic form a for use in the prevention of heterotopic ossification |
| EP3885339A1 (en) | 2020-03-27 | 2021-09-29 | Rottapharm Biotech S.r.l. | Process for the preparation of (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof |
| JPWO2022102731A1 (pt) | 2020-11-13 | 2022-05-19 | ||
| CN112608271A (zh) * | 2020-11-26 | 2021-04-06 | 安润医药科技（苏州）有限公司 | 酰胺衍生物及其在制备ep4受体拮抗剂中的应用 |
| WO2022161423A1 (zh) * | 2021-01-28 | 2022-08-04 | 深圳晶泰科技有限公司 | 环胺衍生物及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100429950B1 (ko) * | 1995-07-31 | 2004-06-16 | 시오노기세이야쿠가부시키가이샤 | 포스포리파제에이2저해활성을갖는피롤리딘유도체 |
| EP1452527B1 (en) | 2001-11-13 | 2009-03-04 | Shiseido Co., Ltd. | Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation |
| US20060167081A1 (en) * | 2002-10-25 | 2006-07-27 | Xavier Billot | Ep4 receptor agonists |
| MXPA05007341A (es) * | 2003-01-10 | 2005-09-30 | Hoffmann La Roche | Derivados de 2-piperidona como agonistas de prostaglandina. |
| US7256211B1 (en) * | 2003-01-21 | 2007-08-14 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivatives and medical use thereof |
| KR100747401B1 (ko) | 2003-09-03 | 2007-08-08 | 화이자 인코포레이티드 | 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물 |
| EA200601830A1 (ru) * | 2004-05-04 | 2007-04-27 | Пфайзер Инк. | Ортозамещённые арильные или гетероарильные амидные соединения |
| JP4054368B2 (ja) | 2004-05-04 | 2008-02-27 | ファイザー株式会社 | 置換メチルアリール又はヘテロアリールアミド化合物 |
| TW200730474A (en) * | 2005-12-29 | 2007-08-16 | Schering Ag | Diamine derivatives as inhibitors of leukotriene A4 hydrolease |
| CA2648729A1 (en) | 2006-04-24 | 2007-11-01 | Merck Frosst Canada Ltd. | Indole amide derivatives as ep4 receptor antagonists |
| US8158671B2 (en) | 2007-02-26 | 2012-04-17 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
| PT2565191E (pt) * | 2008-05-14 | 2014-12-04 | Astellas Pharma Inc | Derivados do ácido 4-(indol-7- ilcarbonilaminometil)ciclo-hexanocarboxílico como antagonistas de receptores ep4, úteis no tratamento de insuficiência renal crónica ou de nefropatia diabética |
| WO2010148197A1 (en) | 2009-06-17 | 2010-12-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| EP2275421A1 (en) | 2009-07-15 | 2011-01-19 | Rottapharm S.p.A. | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction |
| WO2013004291A1 (en) * | 2011-07-04 | 2013-01-10 | Rottapharm S.P.A. | Cyclic amine derivatives as ep4 receptor agonists |
-
2011
- 2011-07-04 IN IN719CHN2014 patent/IN2014CN00719A/en unknown
- 2011-07-04 KR KR1020147001964A patent/KR101760164B1/ko active IP Right Grant
- 2011-07-04 US US14/130,451 patent/US9181279B2/en active Active
- 2011-07-04 DK DK11743035.5T patent/DK2729445T3/en active
- 2011-07-04 HU HUE11743035A patent/HUE028439T2/en unknown
- 2011-07-04 PL PL11743035T patent/PL2729445T3/pl unknown
- 2011-07-04 WO PCT/EP2011/061226 patent/WO2013004290A1/en active Application Filing
- 2011-07-04 CN CN201180072023.8A patent/CN103702980B/zh active Active
- 2011-07-04 CA CA2839116A patent/CA2839116C/en active Active
- 2011-07-04 EP EP11743035.5A patent/EP2729445B1/en active Active
- 2011-07-04 RU RU2014103587/04A patent/RU2565596C2/ru active
- 2011-07-04 AU AU2011372747A patent/AU2011372747B2/en active Active
- 2011-07-04 JP JP2014517473A patent/JP5813223B2/ja active Active
- 2011-07-04 ES ES11743035.5T patent/ES2559513T3/es active Active
- 2011-07-04 BR BR112014000087-5A patent/BR112014000087B1/pt active IP Right Grant
-
2012
- 2012-06-15 TW TW101121493A patent/TWI546285B/zh active
- 2012-07-04 AR ARP120102418A patent/AR087052A1/es active IP Right Grant
-
2014
- 2014-09-09 HK HK14109116.4A patent/HK1195901A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2729445T3 (pl) | 2016-04-29 |
| CA2839116C (en) | 2019-07-16 |
| JP5813223B2 (ja) | 2015-11-17 |
| AU2011372747A1 (en) | 2014-02-06 |
| CN103702980A (zh) | 2014-04-02 |
| AR087052A1 (es) | 2014-02-12 |
| AU2011372747B2 (en) | 2016-12-22 |
| EP2729445A1 (en) | 2014-05-14 |
| HK1195901A1 (zh) | 2014-11-28 |
| TWI546285B (zh) | 2016-08-21 |
| RU2014103587A (ru) | 2015-08-20 |
| CA2839116A1 (en) | 2013-01-10 |
| DK2729445T3 (en) | 2016-01-18 |
| CN103702980B (zh) | 2016-10-05 |
| KR20140048215A (ko) | 2014-04-23 |
| TW201302700A (zh) | 2013-01-16 |
| US20150087626A1 (en) | 2015-03-26 |
| ES2559513T3 (es) | 2016-02-12 |
| HUE028439T2 (en) | 2016-12-28 |
| KR101760164B1 (ko) | 2017-07-20 |
| WO2013004290A1 (en) | 2013-01-10 |
| BR112014000087B1 (pt) | 2021-08-17 |
| IN2014CN00719A (pt) | 2015-04-03 |
| RU2565596C2 (ru) | 2015-10-20 |
| JP2014522821A (ja) | 2014-09-08 |
| EP2729445B1 (en) | 2015-10-21 |
| US9181279B2 (en) | 2015-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014000087A2 (pt) | derivados de amina cíclica como antagonistas do receptor ep4 | |
| HK1210139A1 (en) | Novel benzimidazole derivatives as ep4 antagonists ep4 | |
| BR112013023068A2 (pt) | derivados de isoxazolina espirocíclica como agentes antiparasíticos | |
| BR112013028983A2 (pt) | antagonistas mdm2 espiro-oxindol | |
| BR112014008590A2 (pt) | métodos de uso de antagonistas de scd1 | |
| HK1252279A1 (zh) | 5- ht3受體拮抗劑 | |
| HK1190703A1 (zh) | 雜環胺衍生物 | |
| DK2821407T3 (da) | Piperidinoncarboxamidazaindan-cgrp receptorantagonister | |
| IL228945A0 (en) | Modified bicyclylmethylamine derivatives as sphingosine-1-phosphate receptor modulators | |
| CO6821953A2 (es) | Antagonistas de trpv4 | |
| HK1202540A1 (en) | Heteroaromatic methyl cyclic amine derivative | |
| CO6970595A2 (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
| HK1203932A1 (en) | Heterocyclic amide derivatives as p2x7 receptor antagonists p2x7 | |
| HK1196357A1 (zh) | 作為痕量胺相關受體 的雜環衍生物 | |
| CO6811856A2 (es) | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina | |
| EP2685824A4 (en) | INDOLE DERIVATIVES USEFUL AS CCR2ANTAGONISTS | |
| CO6801731A2 (es) | Compuesto de pirazol como antagonistas de crth2 | |
| BR112013024074A2 (pt) | derivado de isoxazolina como agentes antiparasitários | |
| BR112015005750A2 (pt) | antagonistas peptídicos do receptor de vasopressina-2 | |
| CO6821933A2 (es) | Antagonistas no competitivos de receptores nicotínicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B04C | Request for examination: application reinstated [chapter 4.3 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: ROTTAPHARM BIOTECH S.R.L. (IT) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/07/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |